Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID C PURSELLE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1356384135
CMS profile
715381
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$80,699.19

132 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID C PURSELLE

NPI 1356384135 · CMS profile ID 715381

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356384135?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID C PURSELLE, NPI 1356384135, CMS profile ID 715381. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356384135?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID C PURSELLE, NPI 1356384135, CMS profile ID 715381. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356384135?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID C PURSELLE, NPI 1356384135, CMS profile ID 715381, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1356384135?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

132 matching records · $80,699.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 132 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 132.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka Pharmaceutical Development & Commercialization, Inc. $452.7807/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325645 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $384.2507/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325647 CMS
Otsuka America Pharmaceutical, Inc. $2.5207/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227458588 CMS
Otsuka America Pharmaceutical, Inc. $2.6807/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227458592 CMS
Otsuka America Pharmaceutical, Inc. $23.1407/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227458595 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $104.8307/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325633 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $199.3407/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325635 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $318.6907/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325637 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $650.3407/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325639 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $45.0007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325641 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $50.0007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325643 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $45.0007/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325629 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $50.0007/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325631 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $45.0007/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325625 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $50.0007/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225325627 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $318.6907/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325621 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $589.4607/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225325623 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $12,656.2507/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225325617 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $1,944.0007/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225325619 CMS
Otsuka America Pharmaceutical, Inc. $18.3506/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227458584 CMS
E.R. Squibb & Sons, L.L.C. $22.9006/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184605626 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.0006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241384792 CMS
ABBVIE INC. $14.7205/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203704552 CMS
ABBVIE INC. $3.4505/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203704544 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.0005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241384790 CMS
Otsuka America Pharmaceutical, Inc. $21.8605/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227458580 CMS
Tris Pharma Inc $23.9904/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1192287553 CMS
ABBVIE INC. $4,725.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1203704538 CMS
Otsuka America Pharmaceutical, Inc. $26.0304/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227458576 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $351.0004/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225325615 CMS
ABBVIE INC. $8.2104/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203704532 CMS
Neurocrine BioSciences, Inc. $292.0004/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242960025 CMS
Neurocrine BioSciences, Inc. $65.0004/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242969934 CMS
Neurocrine BioSciences, Inc. $50.0004/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242971018 CMS
Neurocrine BioSciences, Inc. $37.9204/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242974375 CMS
Neurocrine BioSciences, Inc. $37.9004/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242974431 CMS
Neurocrine BioSciences, Inc. $584.0004/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242958793 CMS
Neurocrine BioSciences, Inc. $568.1704/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242958815 CMS
Neurocrine BioSciences, Inc. $175.0004/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242961419 CMS
Neurocrine BioSciences, Inc. $74.8404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242969328 CMS
Neurocrine BioSciences, Inc. $49.9404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242971172 CMS
Neurocrine BioSciences, Inc. $37.9504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242974317 CMS
Neurocrine BioSciences, Inc. $37.8704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242974510 CMS
ABBVIE INC. $251.8304/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1203704492 CMS
ABBVIE INC. $4.5204/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203704499 CMS
ABBVIE INC. $23.6104/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203704504 CMS
ABBVIE INC. $235.7604/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1203704515 CMS
ABBVIE INC. $384.9604/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1203704520 CMS
ABBVIE INC. $103.4504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203704526 CMS
Neurocrine BioSciences, Inc. $139.9704/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242962935 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,966.89 46
PY2020 $5,074.60 61
PY2021 $7,324.89 73
PY2022 $56,226.66 112
PY2023 $91,826.55 169
PY2024 $57,152.26 133
PY2025 $80,699.19 132

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $388,846.14 71
PY2024 Principal investigator $342,162.72 44
PY2023 Principal investigator $394,898.68 139
PY2022 Principal investigator $339,818.09 45
PY2021 Principal investigator $1,155,903.90 84
PY2020 Principal investigator $2,737,150.21 271
PY2019 Recipient $1,852.95 10
PY2019 Principal investigator $1,705,217.84 206

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,255.00 12/25/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175424999
Principal investigator 1 Janssen Research & Development, LLC $1,255.00 12/05/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175425011
Principal investigator 1 Janssen Research & Development, LLC $1,986.00 10/30/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175425005
Principal investigator 1 ABBVIE INC. $4,557.51 10/15/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202517057
Principal investigator 1 ABBVIE INC. $3,848.64 10/15/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202517059
Principal investigator 1 ABBVIE INC. $1,350.00 10/01/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202513020
Principal investigator 1 Janssen Research & Development, LLC $1,255.00 09/29/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175424977
Principal investigator 1 Janssen Research & Development, LLC $1,300.00 09/01/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175424983
Principal investigator 1 Janssen Research & Development, LLC $7,408.00 07/30/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175424994
Principal investigator 1 Celgene Corporation $17,674.92 07/14/2025 Non-covered Recipient Entity
Advanced Discovery Research
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1222306525
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 07/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713246
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,100.00 06/02/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220806411
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 06/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713234
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713236
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713238
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713240
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713242
Principal investigator 1 Janssen Research & Development, LLC $13,019.00 05/29/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175424989
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,628.86 05/27/2025 Non-covered Recipient Entity
Advanced Discovery Research
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235999349
Principal investigator 1 ABBVIE INC. $8,130.48 05/16/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202485393
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,607.22 05/08/2025 Non-covered Recipient Entity
Advanced Discovery Research
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235999351
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 05/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713224
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713226
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713228
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713230
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713232
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,278.00 04/28/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220806409
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713244
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713218
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713220
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 04/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713222
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $66,358.00 03/28/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220806407
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 03/25/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713212
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713214
Principal investigator 1 ABBVIE INC. $2,629.68 03/19/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464843
Principal investigator 1 Sumitomo Pharma America, Inc. $2,551.00 03/19/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630571
Principal investigator 1 Sumitomo Pharma America, Inc. $1,750.00 03/19/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630580
Principal investigator 1 Sumitomo Pharma America, Inc. $2,040.14 03/19/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630584
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,500.00 03/12/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
ITI-007-321 No dispute reported 06/30/2026 1242336705
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,898.00 03/12/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
ITI-007-321 No dispute reported 06/30/2026 1242336707
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 03/12/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
ITI-007-321 No dispute reported 06/30/2026 1242336709
Principal investigator 1 Sumitomo Pharma America, Inc. $546.60 03/03/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176629954
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713192
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713194
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713196
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713198
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 03/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713200
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $113,105.00 03/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220806405
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,012.00 02/27/2025 Non-covered Recipient Entity
Research Centers Of America
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220795491
Principal investigator 1 Boehringer Ingelheim International GmbH $459.54 02/25/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713206
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 02/25/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713208
Principal investigator 1 Boehringer Ingelheim International GmbH $27.36 02/25/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713210
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $9,529.19 02/19/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335521
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713182
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713184
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713186
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713188
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713190
Principal investigator 1 Sumitomo Pharma America, Inc. $1,750.00 01/28/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176624732
Principal investigator 1 Sumitomo Pharma America, Inc. $2,710.63 01/28/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176624736
Principal investigator 1 Sumitomo Pharma America, Inc. $1,976.00 01/28/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176624748
Principal investigator 1 Sumitomo Pharma America, Inc. $4,846.00 01/28/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176624781
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 01/27/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713202
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 01/27/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713204
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,500.00 01/10/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
ITI-007-602 No dispute reported 06/30/2026 1242328586
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,052.00 01/10/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
ITI-007-602 No dispute reported 06/30/2026 1242328588
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 01/10/2025 Non-covered Recipient Entity
ADVANCED DISCOVERY RESEARCH LLC
ITI-007-602 No dispute reported 06/30/2026 1242328590
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,500.00 01/09/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220806403
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713178
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713180
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Advanced Discovery Research LLC
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220713216